Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients-Reference-Cited by-同舟云学术

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

Published:2013-03 Issue:2 Volume:7 Page:154-160
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:Journal of Crohn's and Colitis

Author:

Baert Filip,Glorieus Elien,Reenaers Cathérine,D'Haens Geert,Peeters Harald,Franchimont Dennis,Dewit Olivier,Caenepeel Philippe,Louis Edouard,Van Assche Gert

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/7/2/154/1307472/7-2-154.pdf

Reference13 articles.

1. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial;Hanauer;Gastroenterology,2006

2. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial;Sandborn;Ann Intern Med,2007

3. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease;Karmiris;Gastroenterology,2009

4. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients;Swoger;Inflamm Bowel Dis,2010

5. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004–2008);Ho;Aliment Pharmacol Ther,2009

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study;BioDrugs;2024-08-22

2. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

3. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

4. De-escalation of Biologic Treatment in Inflammatory Bowel Disease: A Comprehensive Review;Journal of Crohn's and Colitis;2023-11-01

5. Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease;Digestive Diseases and Sciences;2023-09-19